<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib by increase of its absorption by the amiodarone</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZAPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the carbamazepine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CICLOSPORIN" rxcui="3008">
<ATC code="L04AD01" />
<ATC code="S01XA18" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib by increase of its absorption by the ciclosporin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERYTHROMYCIN" rxcui="4053">
<ATC code="D10AF02" />
<ATC code="D10AF52" />
<ATC code="J01FA01" />
<ATC code="S01AA17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib by increase of its absorption by the erythromycin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib by increase of its absorption by the ritonavir boosted protease inhibitor</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib by increase of its absorption by the itraconazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib by increase of its absorption by the ketoconazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the St Johns Wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the phenytoin or the fosphenytoin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the nintedanib by decrease of its absorption by the rifampicin</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>381-NINTEDANIB.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="LO1XE31" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the nintedanib by increase of its absorption by the verapamil</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring during the administration of these medications together</COMMENT>
</INTERACTION>
</INTERACTIONS>
